Companies › Friendi.fi
2 active drug programs in 2 registered trials: 2 Phase 1; Neurology; next expected readout May 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Digital STEADI-1 Tablet-based avatar delivering STEADI fall risk screening, monitoring and exercise program | – | Phase 1 | Fall | May 2028 |
| Digital STEADI-2 SMS chat-based delivery of STEADI fall risk screening, monitoring and exercise program | – | Phase 1 | Fall | May 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07852650 | Digital STEADI-1 | Phase 1 | Fall | Neurology | May 2028 |
| NCT07852650 | Digital STEADI-2 | Phase 1 | Fall | Neurology | May 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.